Drug review fees in Europe to increase

03/11/2013 | In-PharmaTechnologist.com

The European Medicines Agency anticipates that fees for drug reviews will increase approximately 2.6% beginning in April, primarily to account for inflation. The EMA has also announced that it will reduce the current 75% fee reduction it offers for production of orphan drugs and use part of the additional revenue to fund salary and benefit increases.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA